Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2014
Pharmacy Choice - News - Front Page Healthcare News - April 23, 2014

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/23/14 - Aetna Completes Acquisition of Interglobal Group
LONDON& HARTFORD, Conn. Aetna today announced that it has completed its acquisition of United Kingdom- based InterGlobal from a group led by its majority shareholder Alchemy Partners. InterGlobal specializes in international private medical insurance for groups and individuals in the Middle East, Asia, Africa and Europe. Aetna Media Contact: Cy
4/23/14 - Alder Biopharma Reports Data from PoC Clinical Trial of ALD403, Will Be Presented at AANM
Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King's College London and director, Headache Center, Department of Neurology, University of California, San Francisco, will present results from a randomized, double-blind, placebo-controlled proof-of-conce
4/23/14 - American Health Network Live with eClinicalWorks for Population Health
eClinicalWorks , a leader in ambulatory healthcare IT solutions, today announced American Health Network is live using eClinicalWorks Care Coordination Medical Record for population health management to manage three Accountable Care Organizations American Health Network of Ohio Care Organization, Franciscan AHN ACO and Indiana Care...
4/23/14 - Baxter Announces FDA Approval of ADVATE (Antihemophilic Factor [Recombinant]) with BAXJECT III Reconstitution System
Baxter International Inc. today announced that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE. ''ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their treatment with fewer steps
4/23/14 - BioLineRx Secures Approval for Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment [Professional Services Close - Up]
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's...
4/23/14 - Calgary Scientific Receives FDA Clearance for Mobile Diagnosis on all Modalities
By a News Reporter-Staff News Editor at Biotech Week Calgary Scientific Inc., a company known for creating transformative technology for the medical industry and beyond, announced their latest Class II clearance from the United States Food and Drug Administration. Calgary Scientific worked closely with a number of Radiologists at a world renowned
4/23/14 - Cancer care providers confront challenges [The Sentinel, Carlisle, Pa. :: ]
April 22 HARRISBURG Each day in 2012, an average of 108 men and 109 women in Pennsylvania learned they had cancer. Cancer death rates are down and survival rates are up, but the number of new cancer cases is on the rise in Pennsylvania and throughout the nation. Heine has joined physician advocates with the Pennsylvania Society of Oncology and
4/23/14 - Colorado Awards HP $116 Million Medicaid Contract
Release date- 22042014- PALO ALTO, Calif.- HP Enterprise Services today announced the Colorado Department of Health Care Policy and Financing has signed a $116.9 million contract for HP to implement a new Medicaid management system. HP will serve as the state's Medicaid fiscal agent to strengthen operations and support Colorado's healthcare reform.
4/23/14 - DIRECTOR DEALINGS: Sinclair Non-Executive Acquires Shares
LONDON- Sinclair IS Pharma PLC said Wednesday that Non-Executive Director Stuart Swanson has acquired 19,089 shares at a price of 30.5 pence per share on Tuesday. Following this transaction, Swanson holds 4.3 million shares representing 0.99% in the pharmaceutical company. Sinclair shares were trading at 30.86 pence Wednesday midday, down 0.04%.
4/23/14 - DNA alternative to Pap smear sparks medical debate [Malta Independent, The]
While such technology has been available for years, Roche now wants the Food and Drug Administration to approve its test as a first-choice option for cervical cancer screening, bypassing the decades-old Pap test. The letter, dated Monday, is signed by 17 patient advocacy groups, including Consumers Union, the Cancer Prevention and Treatment Fund an
4/23/14 - Eli Lilly will buy Novartis division [News & Record, Greensboro, N.C. :: ]
April 23 An Indianapolis drug maker will acquire Novartis' animal-health division, which is headquartered in Greensboro, in a $5.4 billion deal announced Tuesday. Novartis AG is a pharmaceutical company based in Basel, Switzerland. Eli Lilly will acquire Novartis' nine manufacturing sites, six research and development facilities, a portfolio of 6
4/23/14 - Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Disease or...
Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Disease or Conditions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability. FDA believes that the Expedited Access PMA program will help patients have more timely access to these...
4/23/14 - Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA
Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug Application amendment to evaluate PROHEMA in pediatric patients undergoing hematopoietic stem cel
4/23/14 - Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients
Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug Application amendment to evaluate PROHEMA in pediatric patients undergoing hematopoietic stem c
4/23/14 - FDA Announces Availability of Draft Guidance Entitled 'Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for...
WASHINGTON, April 23 The U.S. Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Disease or Conditions; Draft Guidance for Ind
4/23/14 - FDA Clears Siemens SOMATOM Force CT System
Siemens Healthcare has announced that the U.S. Food and Drug Administration has cleared the SOMATOM Force computed tomography system the next generation in dual source CT. With two sets of Siemens most innovative X-ray tubes and detectors, the SOMATOM Force extends advanced imaging to all patients, including some of the most challenging: y
4/23/14 - FDA Grants Orphan Drug Designation for Bayer's Investigational Ciprofloxacin Dry Powder for Inhalation for Treatment of NCFB
Release date- 22042014- Berlin,- Bayer HealthCare today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted an orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation for the treatment of non-cystic fibrosis bronchiectasis. Jorg Moller, Member of the Bayer HealthCa
4/23/14 - FDA proposes new expedited access program for medical devices that address unmet medical needs
Release date- 22042014- Today, the U.S. Food and Drug Administration proposed a new program to provide earlier access to high-risk medical devices that are intended to treat or diagnose patients with serious conditions whose medical needs are unmet by current technology. The proposed Expedited Access Premarket Approval Application for Unmet Medical
4/23/14 - FDAnews Announces: Preparing for the New eCTD Mandates Workshop, June 10-11, 2014, Bethesda, MD
Preparing for the New eCTD Mandates: Mastering the Tools and Strategies** Presented by FDAnews and e-SubmissionsSolutions.com** June 10-11, 2014 Bethesda, MD http://www.fdanews.com/eCTDBethesda. Many drug, biologic and device companies utilizing eCTD can already measure a striking difference through increased first time acceptance rates, shorter
4/23/14 - Findings in Tachycardia Reported from Children's Hospital
For more information on this research see: Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation, 2014; 85: 381-386. Resuscitation can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Par
4/23/14 - GE Healthcare Receives FDA Clearance For Q.Clear Technology
By a News Reporter-Staff News Editor at Biotech Week GE Healthcare, a unit of General Electric Company, announced that it received U.S. FDA 510 clearance of its Q.Clear ^ technology- technology that can provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. GE Healthcare's new Q.Clear technology sho
4/23/14 - Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA
Release date- 22042014- FOSTER CITY, Calif.- Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or' boosting' agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily do
4/23/14 - iCAD Posts Results of Its Xoft System to Treat Skin Cancer [Professional Services Close - Up]
iCAD, Inc., a provider of imaging and radiation therapy for the early identification and treatment of cancer, announced that more than 4,000 non-melanoma skin cancer patients have been treated using the Xoft Axxent Electronic Brachytherapy System demonstrating continued growth and utilization of the system among radiation oncologists and...
4/23/14 - iCAD Updates on Its Xoft System [Manufacturing Close - Up]
iCAD, Inc., a provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, announced that more than 4,000 non-melanoma skin cancer patients have been treated using the Xoft Axxent Electronic Brachytherapy System demonstrating continued growth and utilization of the system among radiation oncologists and..
4/23/14 - iCare Collaborates with Casenet to Deliver Advanced Support for Home and Community-Based Services
Casenet, LLC, a leading provider of extensible care management solutions, today announced its collaboration with Independent Care Health Plan to deliver home and community-based services to its members using TruCare . "The ability to quickly determine what home and community-based programs our members are eligible for and easily enroll them ensu
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415